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Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone
receptor superfamily that regulate diverse physiological processes ranging from lipogenesis to inﬂammation. Recent evidence has
established potential roles of PPARs in both systemic and pulmonary vascular disease and function. Existing treatment strate-
gies for pulmonary hypertension, the most common manifestation of pulmonary vascular disease, are limited by an incomplete
understanding of the underlying disease pathogenesis and lack of eﬃcacy indicating an urgent need for new approaches to treat
this disorder. Derangements in pulmonary endothelial-derived mediators and endothelial dysfunction have been shown to play a
pivotal role in pulmonary hypertension pathogenesis. Therefore, the following review will focus on selected mediators implicated
in pulmonary vascular dysfunction and evidence that PPARs, in particular PPARγ, participate in their regulation and may provide
a potential novel therapeutic target for the treatment of pulmonary hypertension.
Copyright © 2007 Rachel E. Nisbet et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Originally described in 1990, peroxisome proliferator-
activated receptors (PPARs) are ligand-activated transcrip-
tion factors belonging to the nuclear hormone receptor su-
perfamily [1]. PPARs have been implicated in diverse dis-
orders including cancer, diabetes, and atherosclerosis, and
activation of these receptors regulates diverse physiolog-
ical processes ranging from lipogenesis to inﬂammation.
Three distinct PPAR subclasses have been identiﬁed; PPARα,
PPARβ/δ,a n dP P A R γ. These isotypes are encoded by sepa-
rate genes and exhibit diﬀerent tissue distributions and func-
tion. PPARα is predominantly expressed in liver, heart, kid-
ney, and muscle where it regulates genes involved in lipid
metabolism. PPARβ/δ is a more ubiquitously expressed iso-
form that stimulates fatty acid oxidation in heart and skele-
tal muscle [2] and whose diverse functions include cell dif-
ferentiation [3] and participation in placental development,
cancer[4],woundrepair[5],andatherosclerosis[6].PPARγ,
expressed in many tissues including adipose, vascular en-
dothelium and smooth muscle, and heart among others, is
an important regulator of genes involved in cellular diﬀeren-
tiation, particularly adipogenesis, lipid metabolism, and glu-
cose homeostasis. More recently, PPARγ has been shown to
play a pivotal role in cell growth, inﬂammation, apoptosis,
and angiogenesis [7–10]. There is limited evidence for the
potential roles of PPARα and PPARβ/δ in pulmonary vas-
cular function and disease. However, recent studies have es-
tablished that pulmonary hypertension in humans is associ-
ated with reduced PPARγ expression and that PPARγ ligands
can attenuate the development of pulmonary hypertension
in several experimental models. This review will summarize
recent work implicating PPARγ in pulmonary vascular dis-
ease.
2. PPAR BIOLOGY
Ligand binding stimulates the PPAR to form a heterodimer
with the retinoid X receptor (RXR) in the cytoplasm [11].
Once activated, the PPAR/RXR heterodimer translocates to
the nucleus where the complex binds to PPAR response ele-
ments (PPRE) in the promoter region of responsive genes to
modulate transcriptional activity. Gene regulation involves
ligand-induced conformational changes in the PPAR recep-
tor that mediate interaction with speciﬁc coactivator (e.g.
steroid receptor coactivator-1 and p300) and corepressor
molecules. The coactivator proteins either possess histone
acetyltransferase activity or recruit other proteins with this2 PPAR Research
activity to the transcription start site. Acetylation of histone
proteins alters chromatin structure, facilitating the binding
of RNA polymerase and the initiation of transcription [12].
PPARs can also repress gene expression by interfering with
other signaling pathways and by recruiting corepressors to
unliganded PPARs [13].
Structurally diverse ligands activate PPARs. For exam-
ple, ligands of PPARα include polyunsaturated fatty acids,
arachidonicacidmetabolitessuchasleukotrieneB4,andsyn-
thetic ﬁbrate compounds used in the treatment of dyslipi-
demia. Ligands for PPARβ/δ continue to be deﬁned and in-
clude prostacyclin suggesting a potential role for PPARβ/δ in
regulationofvasculartone,plateletaggregation,andcellpro-
liferation[14,15].Ontheotherhand,PPARγ ligandsinclude
the thiazolidinedione class of anti-diabetic medications (e.g.
pioglitazone, rosiglitazone, and troglitazone), components
of oxidized low-density lipoprotein [16], nitrated fatty acids
(nitroalkenes), long chain fatty acids and their metabolites,
and the PGD2 metabolite, 15-deoxy-Δ12,14-prostglandin J2
(15d-PGJ2). However, despite this promiscuity for activating
ligands and broad tissue distribution, speciﬁcity of PPAR-
mediated tissue eﬀects occurs, in part, through recruitment
of ligand-speciﬁc populations of coactivator and corepressor
molecules [17–19].
3. PATHOGENESIS OF PULMONARY VASCULAR
DYSFUNCTION
The appreciation of the potential role of PPARγ in pul-
monary vascular disease derives from several basic concepts
of vascular disease pathogenesis. Current evidence indicates
that endothelial dysfunction and derangements in the bal-
anced production of vasodilatory and vasoconstrictive me-
diators play a critical role in both systemic [20, 21] and pul-
monary vascular [22] diseases. Within the systemic circula-
tion, endothelial dysfunction represents an early step in the
pathogenesis of atherosclerotic vascular disease that culmi-
nates in coronary, peripheral vascular and cerebrovascular
disease.
Incontrast,pulmonaryhypertensionrepresentsthemost
common manifestation of pulmonary vascular disease. Pul-
monary hypertension is characterized by pulmonary vaso-
constrictionandvascularsmoothmusclecellandendothelial
cell proliferation. Deﬁned as elevation of mean pulmonary
artery pressure above 25mmHg at rest or above 30mmHg
with exercise, pulmonary hypertension caused 15 668 deaths
and 260 000 hospital visits in the United States in 2002
[23]. Pulmonary hypertension is most commonly caused
by diverse clinical conditions that produce chronic contin-
uous or intermittent alveolar hypoxia including chronic ob-
structive pulmonary disease, obstructive sleep apnea, or liv-
ing at altitude. These conditions promote pulmonary vaso-
constriction, vascular remodeling, and pulmonary hyper-
tension. Less commonly, pulmonary hypertension devel-
ops secondary to congenital heart defects, autoimmune dis-
eases, left-sided heart failure, or ingestion of certain anorex-
igen drugs or as a consequence of derangements in bone
morphogenetic protein receptor signaling [24, 25]. Existing
treatment strategies for patients with pulmonary hyperten-
sion are limited by an incomplete understanding of the un-
derlying disease pathogenesis, high cost, and lack of eﬃcacy
indicating an urgent need for new approaches to our under-
standing and treatment of this disorder.
Abundant evidence in humans and animal models indi-
cates that derangements in pulmonary endothelial-derived
mediators and endothelial dysfunction play a pivotal role
in pulmonary hypertension pathogenesis. Many of these en-
dothelial mediators are also impacted by PPARγ. The follow-
ing summarizes what is known about the interplay between
PPARγ and these mediators.
3.1. Nitricoxide
Nitric oxide (NO) has been studied extensively as an
endothelium-derived mediator that plays a critical role in
normal vascular function and that promotes a host of vascu-
lar protective eﬀects. For example, NO inhibits smooth mus-
cle proliferation [26] and platelet aggregation [27], reduces
endothelin-1 (ET-1) production [28], and protects against
hypoxia-induced vasoconstriction [29]. Although chronic
hypoxia causes pulmonary vasoconstriction through com-
plex mechanisms, compelling evidence indicates that dysreg-
ulation of vascular endothelial function constitutes a crit-
ical event in the pathogenesis of pulmonary hypertension
[22]. These endothelial derangements include alterations in
the proliferative capacity of vascular endothelium as well as
derangements in endothelium-derived mediators that mod-
ulate vascular smooth muscle cell function such as NO,
ET-1, serotonin, and prostanoids [30, 31]. While impaired
NO bioavailability contributes to pulmonary hypertension
[32, 33], the relationship between endothelial nitric oxide
synthase (eNOS) expression and pulmonary hypertension is
not clear as reports have variously described reduced, un-
changed, or increased levels of the enzyme [34–37]. Per-
haps this is not surprising given that eNOS-mediated NO
production is regulated by complex mechanisms including
co-factor availability [38–40], eNOS phosphorylation [41–
43], and protein-protein interactions [44–48]. Thus, pul-
monary hypertension-associated alterations in these regula-
tory mechanisms as well as in eNOS expression determine
rates of NO production in the pulmonary circulation.
Once NO is produced, its bioavailability can also be reg-
ulated by levels of other reactive targets in the surrounding
vicinity. For example, superoxide reacts with NO at an ex-
tremely rapid, diﬀusion-limited rate to form the potent oxi-
dant, peroxynitrite [49]. This reaction not only diverts NO
from its generally salutary eﬀects on physiological down-
streamsignalingpathwaysbutcansimultaneouslyleadtoox-
idation of the eNOS cofactor, tetrahydrobiopterin, causing
eNOS uncoupling and eNOS-mediated production of super-
oxide rather than NO [50, 51]. These ﬁndings support evi-
dence for impaired endothelium-derived, NO-mediated va-
sodilation in pulmonary hypertension [52]. The ability of
NO inhalation to improve pulmonary hemodynamics and
quality of life in selected patients with pulmonary hyper-
tension [53] further suggests the importance of relative NORachel E. Nisbet et al. 3
deﬁciency in this disorder. Collectively these and other stud-
ies indicate that post-translational alterations in eNOS regu-
lation and/or enhanced NO degradation rather than reduced
eNOS expression contribute signiﬁcantly to pulmonary hy-
pertension pathogenesis [38, 44, 46, 47].
NADPH oxidase is an important source of superoxide in
pulmonary vasculature, and its stimulation by hypoxic con-
ditions has been recognized for at least 10 years [54]. Re-
centpublicationshaveconﬁrmedtheimportanceofNADPH
oxidase-derived reactive oxygen species in hypoxia-induced
pulmonary hypertension. For example, in isolated-perfused
lung preparations from wild-type mice, ventilation with
3% oxygen caused acute vasoconstrictor responses whereas
hypoxic-induced vasoconstriction was blunted in NADPH
oxidase deﬁcient, p47phox knockout mice [55]. Similarly,
C57Bl/6 mice exposed to 10% oxygen for 3 weeks demon-
strated increased superoxide generation in pulmonary ar-
teries and increased right ventricular pressure and pul-
monary arterial medial wall thickness [56]. These hypoxia-
induced derangements were completely attenuated in sim-
ilarly treated NADPH oxidase deﬁcient, gp91phox knockout
mice. In a separate report, these same investigators demon-
strated that chronic hypoxia enhanced ET-1-stimulated pul-
monary arterial vasoconstriction and superoxide genera-
tion and that these ET-1 eﬀects were attenuated in gp91phox
knockout mice [57]. NADPH oxidase appears to reside
in both the endothelial and vascular smooth muscle cell
compartments. Hypoxia stimulated superoxide generation
in segments of intact pulmonary artery and in pulmonary
artery endothelial or vascular smooth muscle cells ex vivo,
and hypoxia-stimulated superoxide generation was inhib-
ited by pharmacological inhibition of NADPH oxidase (with
diphenyliodonium or apocynin) and was associated with en-
hanced gp91phox expression [47]. Taken together, these re-
portsindicatethatNADPHoxidaseisanimportantmediator
of pulmonary hypertension in response to hypoxia and that
it contributes to enhanced vasoconstrictor responses in the
pulmonary circulation following chronic hypoxia.
PPARγ ligands stimulate NO release from endothelial
cells through PPARγ-dependent signaling pathways [58, 59].
This enhanced endothelial NO release was not related to
increased eNOS expression [58, 59] but was mediated, in
part, by alterations in the post-translational regulation of
eNOS that increased enzyme activity [58]. PPARγ ligands
also produced coordinate reductions in endothelial NADPH
oxidaseexpressionandactivityandincreasedCuZnsuperox-
ide dismutase expression and activity [60, 61]. Although ad-
ditional studies will be required to conﬁrm that these eﬀects
ofPPARγ ligandsonsuperoxideproductionanddegradation
are PPARγ-dependent, these ﬁndings suggest that PPARγ
ligands have great potential for favorably modulating NO
bioavailability. Rosiglitazone-induced reductions in NADPH
oxidase activity in a rat model of hypertension further sup-
port the potential of PPARγ ligands to favorably modulate
dysregulated reactive oxygen species production [62]. Taken
together, these ﬁndings suggest that PPARγ ligands can regu-
latethebalancebetweenendothelialNOandsuperoxidepro-
duction and provide insights into potential mechanisms by
which PPARγ ligands could reduce pulmonary endothelial
dysfunction.
PPARγ ligands also exert a variety of other eﬀects on
vascular wall cells that could be mediated, in part, by NO
bioavailability. PPARγ ligands inhibit stimulated plasmino-
gen activator inhibitor-1 production [63], inhibit smooth
muscle cell migration and proliferation [64], and angiogen-
esis [65]. Nitroalkenes, the product of NO and unsaturated
fattyacids,arepotentendogenousPPARγ agoniststhatmod-
ulate PPARγ-regulated signaling events such as adipogenesis
andCD36expressioninmacrophages[66].Nitroalkenesalso
stimulate relaxation of vessel segments in an NO-dependent
manner [67] although their role in vascular regulation re-
mains to be deﬁned. Finally, in models of inﬂammation,
PPARγ ligandsreduceinduciblenitricoxidesynthaseexpres-
sion [68], cytokine-induced monocyte chemotactic protein-
1p r o d u c t i o n[ 69], and endothelial-leukocyte adhesion [70].
Taken together, these reports illustrate that PPARγ plays a
central role in regulating NO bioavailability and emphasize
the potential relevance of PPARγ biology to both systemic
and pulmonary vascular function.
3.2. Endothelin-1
ET-1 is a polypeptide that has been implicated in pulmonary
hypertension pathogenesis. ET-1 is a potent vasoconstric-
tor that promotes platelet aggregation, and its receptors are
upregulated in the lung in both animal models [71, 72]
and patients with pulmonary hypertension [36]. ET-1, as
well as endothelium-derived reactive oxygen species, atten-
uated NO-dependent pulmonary vasodilation following ex-
posure to chronic hypoxia in isolated rat lungs [73]. ET-1-
induced pulmonary vasoconstriction was markedly reduced
by administration of Cu/Zn superoxide dismutase and was
completely attenuated in gp91phox deﬁcient mice [56]. These
ﬁndingssuggestthatNADPHoxidaseandsuperoxideplayan
important role in pulmonary vascular eﬀects of ET-1.
Endothelin-1 receptor antagonists have been employed
in patients with pulmonary hypertension to improve func-
tional status and other indices of pulmonary hypertension-
relatedmorbidity [73],furthersuggestingthatET-1isanim-
portant mediator of pulmonary vascular dysregulation. Lim-
ited evidence suggests that PPAR ligands inhibit ET-1 secre-
tion by vascular endothelial cells [74, 75].
3.3. Prostacyclin
Prostacyclin, another endothelial-derived mediator involved
inpulmonaryvascularregulation,isapotentvasodilatorthat
inhibits platelet aggregation and exerts anti-inﬂammatory,
anti-thrombotic, and anti-proliferative vascular eﬀects [76].
Overexpression of prostacyclin synthase protected mice
from chronic hypoxia-induced pulmonary hypertension
[77] whereas prostacyclin-receptor deﬁcient mice were sen-
sitized to hypoxia-induced pulmonary hypertension [78].
Decreased prostacyclin synthase expression has been noted
in the pulmonary arteries of patients with severe pul-
monary hypertension compared to normal subjects, and the4 PPAR Research
vascular endothelium was found to be the major site of lung
vascular prostacyclin synthase expression [34]. In patients
with pulmonary hypertension, prostacyclin derivatives de-
creased urinary isoprostane metabolites, an index of oxida-
tive stress without altering thromboxane A2 [79]. Currently,
this endothelial-derived mediator is a therapeutic target in
the treatment of pulmonary hypertension [80], however
the precise cellular mechanisms responsible for prostacyclin-
mediated beneﬁts remain to be deﬁned.
Several studies have suggested potential relationships be-
tween PPAR, prostaglandin metabolism, and vascular dis-
ease. For example, inducible cyclooxygenase-2 (COX-2) is
expressed in vascular endothelial cells and promotes vascular
dysfunction [81–83]. The ability of PPARγ ligands to inhibit
COX-2 induction [84] suggests potential relationships be-
tween PPARγ and altered prostaglandin metabolism in vas-
cular dysfunction. PPARβ/δ, a putative receptor for prosta-
cyclin, was involved in prostacyclin-induced increases in en-
dothelial cell survival [85] and has been implicated in the
anti-thrombotic and anti-proliferative actions of prostacy-
clin [14, 15].
3.4. Rho/rhokinase
The small GTPase, Rho, and its associated eﬀector, Rho-
kinase play a central role in diverse cellular functions in-
cluding smooth muscle contraction, cell proliferation, and
gene expression. Several studies have demonstrated that the
Rho/Rho-kinase pathway participates in the pathogenesis
of pulmonary hypertension. Rho-kinase activation was in-
volved in hypoxia-induced pulmonary vasoconstriction [86]
and increased basal pulmonary vascular tone in chroni-
cally hypoxic rats [87]. Rho-kinase inhibition reversed acute
hypoxic vasoconstriction [88] and attenuated the develop-
ment of chronic hypoxia-induced pulmonary hypertension
and vascular remodeling in mice [89]. Long-term inhibition
of Rho-kinase also prevented or reversed monocrotaline-
induced pulmonary hypertension in rats by enhancing
apoptosis and reducing proliferation of pulmonary artery
smooth muscle cells [90]. Interestingly, inhaled Rho-kinase
inhibitors caused selective pulmonary artery pressure re-
duction in several models of pulmonary hypertension [91].
Hypoxia-induced Rho-kinase activation may also contribute
to capillary angiogenesis and sustained vasoconstriction
[92].Collectively,thesedatasuggestthattheRho/Rho-kinase
pathway represents an attractive therapeutic target in pul-
monary hypertension.
Recent evidence demonstrated that PPARγ activation
inhibited the Rho/Rho-kinase pathway through upregula-
tion of the protein tyrosine phosphatase, SHP-2 [93]. The
demonstration that PPARγ ligands increased NO produc-
tion [58, 59] and that NO increased SHP-2 activity and sup-
pressed Rho/Rho kinase activation [94] provides additional
evidence that this pathway may be amenable to manipula-
tion with PPARγ ligands. Thus, the role of PPARγ in the reg-
ulation of the Rho/Rho-kinase pathway during pulmonary
hypertension remains a promising area for continued inves-
tigation.
4. PPARγ AND SYSTEMIC VASCULAR
DISEASE
Todate,amoreextensiveliteraturehasbeendevotedtoinves-
tigation of PPARγ in the systemic than in the pulmonary cir-
culation. In general, PPARγ activation attenuates endothelial
dysfunction and the development of atherosclerosis. These
ﬁndings are reviewed in brief to emphasize common path-
ways involved in PPARγ-mediated regulation of vascular
function. In vivo studies of atherosclerosis in non-diabetic
mouse models, including low-density lipoprotein receptor
or apolipoprotein E-deﬁcient mice, demonstrated that thi-
azolidindione PPARγ ligands reduced lesion formation [95–
97] consistent with PPARγ-mediated vascular protection in
non-diabetic vascular disease. PPARγ activation also inhib-
ited VEGF receptor expression and decreased endothelial
tube formation in rats [65]a sw e l la sr e d u c e dV E G Fa n d
leptin-induced migration of human endothelial cells [98].
Another important step in the development of atherosclero-
sis involves adhesion of inﬂammatory cells to the endothe-
lium.PPARγ activationdecreasedexpressionofseveraladhe-
sion molecules, speciﬁcally VCAM and ICAM in endothelial
cells [99] and reduced monocyte-endothelial cell interaction
[70].
In addition, a growing body of literature in animal
and human subjects indicates that PPARγ ligand ther-
apy is associated with improved endothelial function in
vivo [100–103]. For example, pioglitazone and rosiglita-
zone decreased angiotensin II-induced hypertension and
improved endothelium-dependent vasodilation in the rat
[104]. Several mechanisms have been proposed for the anti-
hypertensive eﬀects of PPARγ ligands such as increased ex-
pression of PPARγ receptors in blood vessels [104], reduced
expression of angiotensin II type I receptors [105], and
more recently, direct inhibition of the Rho/Rho-kinase path-
way [93]. In an ET-1-dependent hypertensive rat model,
rosiglitazone restored endothelium-dependent vasodilation,
diminished hypertension progression, and prevented vascu-
lar remodeling by decreasing ET-1 production and blunting
production of reactive oxygen species [62]. Clinical data in
diabetic subjects have demonstrated that thiazolidinedione
PPARγ ligands: (a) reduced surrogate markers of vascular
disease [101], (b) improved ﬂow-mediated, endothelium-
dependent vasodilation [102], and (c) reduced carotid inti-
mal thickening [106] and neointimal formation after coro-
nary stent placement [107]. The vascular protective eﬀect of
PPARγ ligands in humans was recently extended to nondia-
betic subjects with documented coronary disease; rosiglita-
zone reduced common carotid arterial intima-media thick-
ness progression [108]. Moreover, in healthy, nondiabetic in-
dividuals,rosiglitazonesigniﬁcantlyincreasedﬂow-mediated
endothelium-dependent vasodilation as well as reduced in-
ﬂammatory biomarkers of atherosclerosis [109]. Finally, pi-
oglitazone improved endothelial-dependent dilation in non-
diabetic patientswithcardiovascularriskfactors[110].Large
clinical trials are currently underway that will ultimately
determine if thiazolidinediones alter systemic vascular out-
comes in patients with and without diabetes.Rachel E. Nisbet et al. 5
5. PPARγ AND PULMONARY HYPERTENSION
Several studies have suggested a potential role for PPARγ
in the pathogenesis of pulmonary hypertension. For ex-
ample, PPARγ is abundantly expressed in pulmonary vas-
cular endothelial cells of normal human lung tissue and
is signiﬁcantly reduced in the plexiform lesions of hu-
man subjects with pulmonary hypertension [111]. Reduced
PPARγ expression was also demonstrated in vascular lesions
of a rat model of severe pulmonary hypertension caused
by treatment with a VEGF receptor inhibitor in combina-
tion with hypobaric hypoxia exposure [111]. Furthermore,
loss of PPARγ expression resulted in abnormal prolifera-
tion of apoptosis-resistant endothelial cells. The causal link
between apoptosis and pulmonary hypertension-associated
alterations in PPARγ expression remains to be established.
However, additional evidence that vascular endothelial cell
apoptosis is induced by overexpression of PPARγ or by treat-
ment with 15d-PGJ2 suggests fertile areas for future inves-
tigation [112]. Hypoxia as well as shear stress were impli-
cated in reduced PPARγ expression in human endothelial-
like cell lines [111]. Because oscillatory shear stress downreg-
ulates eNOS and upregulates ET-1 [113] and NADPH oxi-
dase[114,115],theseﬁndingssuggestthatthehemodynamic
derangements in pulmonary hypertension may contribute to
the development or propagation of vascular dysfunction and
that reductions in PPARγ expression during pulmonary hy-
pertension may lead to dysregulated production of a broad
variety of vascular mediators that contribute to pulmonary
vascular remodeling and pulmonary hemodynamic dysfunc-
tion.
Not only does pulmonary hypertension appear to be as-
sociated with reduced PPARγ expression, emerging evidence
suggests that ligand-induced PPARγ activation attenuates
pulmonary vascular dysfunction in animal models of pul-
monary hypertension. For example, PPARγ activation with
either pioglitazone or troglitazone signiﬁcantly reduced pul-
monary hypertension and pulmonary artery wall thicken-
ing in a rat model of monocrotaline-induced pulmonary hy-
pertension [116]. Although the exact mechanisms by which
PPARγ exerts its eﬀects in pulmonary hypertension remain
to be deﬁned, several studies have shown that PPARγ ac-
tivation reduced proliferation of vascular smooth muscle
cells and promoted apoptosis in several cell lines in vitro
[117, 118]. Murine models of pulmonary hypertension are
characterized more by medial thickening of the pulmonary
vasculature and lack the characteristic plexiform lesions
composed of proliferative intraluminal endothelial cells that
characterize human pulmonary hypertension [119]. These
reports indicate that attenuation of monocrotaline-induced
pulmonary hypertension may well be related to the capacity
of PPARγ activation to inhibit vascular smooth muscle cell
proliferation [116].
PPARγ ligands also attenuated hypoxia-induced pul-
monary hypertension. Treatment with rosiglitazone reduced
hypoxia-induced pulmonary artery remodeling in Wistar-
Kyoto rats [120]. In this study rats were randomized to nor-
moxia or hypobaric hypoxia and treated with rosiglitazone
(2.5mg/kg/day) for 3 weeks. Rosiglitazone decreased right
ventricular hypertrophy and pulmonary arterial remodeling.
Moreover, these changes were attributed to the inhibition of
smoothmuscleproliferationandwerenotassociatedwithin-
creasedapoptosisfurthersupportingpreviousﬁndingsinthe
monocrotaline-induced pulmonary hypertension model.
While little is known about the involvement of PPARβ/δ
in pulmonary hypertension, recent data suggest that
PPARβ/δ could be a potential therapeutic target. PPARβ/δ
was activated by prostacyclin [15] suggesting that the ben-
eﬁcial eﬀects of prostacyclin therapy, the current treatment
of choice for many patients with severe pulmonary hyper-
tension, could be mediated in part through activation of
PPARβ/δ. Additionally, treprostinil sodium, a prostacylin
mimetic, activated PPARβ/δ and inhibited proliferation of
human lung ﬁbroblasts at concentrations consistent with a
PPAR rather than a prostacyclin receptor-mediated pathway
[15]. These limited observations suggest that PPARβ/δ de-
serves additional study as a potential therapeutic target for
treatment of pulmonary hypertension.
6. FUTURE DIRECTIONS AND CONCLUSIONS
In unpublished data, we have observed that exposure to
chronic hypoxia (10% oxygen) for 3 weeks reduced lung
PPARγ expression and caused pulmonary hypertension in
C57Bl/6 mice as indicated by elevation of right ventricular
systolic pressure and right ventricular hypertrophy. Treat-
ment with rosiglitazone (10mg/kg/day) by gavage during
the ﬁnal 10 days of this hypoxia exposure regimen atten-
uated pulmonary hypertension and right ventricular hy-
pertrophy. Hypoxia-induced pulmonary hypertension was
also associated with reductions in serum levels of nitrosyl-
hemoglobin (NO-Hgb), an index of NO bioavailability.
Hypoxia-induced alterations in NO bioavailability were not
associatedwithlowereNOSproteinlevels.Thesepreliminary
ﬁndings further support the hypothesis that ligand-induced
PPARγ activation attenuates hypoxia-induced reductions in
NO bioavailability in part by suppressing the generation of
r e a c t i v eo x y g e ns p e c i e st h a ti n a c t i v a t eN Os u c ha ss u p e r -
oxide [61, 120, 121] and in part by promoting eNOS ac-
tivity through modiﬁcation of post-translational regulatory
mechanisms [58]. Taken together, these ﬁndings suggest that
PPARγ may represent a novel potential therapeutic target in
pulmonary hypertension that modulates nitroso-redox bal-
ance in the vasculature. The relationships between PPARγ
andselectedaspectsofendothelialdysfunctioninpulmonary
hypertension are schematically presented in Figure 1.
Current evidence strongly suggests that vascular en-
dothelial dysregulation plays a crucial role in the initiation
and progression of pulmonary hypertension. Moreover, al-
terations in endothelium-derived mediators such as NO, ET-
1, and prostanoids as well as reactive oxygen species have
been established as important mechanisms in the devel-
opment of vascular remodeling leading to pulmonary hy-
pertension. Our understanding of PPARγ biology has pro-
gressed rapidly over the last decade but much remains to be
learned about the mechanisms by which these receptors and6 PPAR Research
E
C
V
S
M
C
Hypoxia
shear stress
↑ NADPH oxidase
↑ PPARγ
O•−
2 +NO
ONOO−
eNOS NO
VSMC proliferation
↓ Platelet
activation
↓ Adhesion
molecule
expression
Vasodilation
Figure 1: The eﬀects of PPARγ activation on reactive oxygen species and nitric oxide production in the vascular wall. Factors including hypoxia
and shear stress increase the production of superoxide in the vascular wall by NADPH oxidase. Superoxide (O
·−
2 ) rapidly reacts with nitric
oxide (NO) generated by endothelial nitric oxide synthase (eNOS) to reduce the bioavailability of NO to stimulate vasodilation and inhibit
vascularsmoothmusclecell(VSMC)proliferation,plateletactivation,andadhesionmoleculeexpression.PPARγ activationinhibitsNADPH
oxidaseexpressionandactivity[61]andstimulatesNOproductioninvascularendothelialcells(EC)[58,59].Theseeﬀectsillustratepotential
mechanisms by which PPARγ activation may favorably modulate pulmonary endothelial dysfunction and pulmonary hypertension.
their ligands regulate the pulmonary vasculature. Identifying
speciﬁc downstream targets regulated by PPARs in the pul-
monary vasculature will facilitate the development of poten-
tial PPAR-related therapeutic strategies for the prevention or
treatment of pulmonary hypertension.
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